SONN — Sonnet Biotherapeutics Holdings Cashflow Statement
0.000.00%
- $24.78m
- $24.46m
- $0.02m
Annual cashflow statement for Sonnet Biotherapeutics Holdings, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -24.3 | -25 | -29.7 | -18.8 | -7.44 |
| Depreciation | |||||
| Non-Cash Items | 7.25 | 1.33 | 1.93 | 0.594 | 0.686 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.4 | 1.09 | 0.093 | -3.12 | -1.87 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -15.6 | -22.6 | -27.7 | -21.3 | -8.61 |
| Capital Expenditures | -0.076 | -0.004 | -0.896 | -0.443 | -0.012 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.076 | -0.004 | -0.896 | -0.443 | -0.012 |
| Financing Cash Flow Items | -5.98 | 0 | — | — | -0.385 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 23 | 42.8 | 4.01 | 21 | 6.49 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.31 | 20.3 | -24.6 | -0.779 | -2.12 |